Steroid minimization in liver transplant recipients: impact on hepatitis C recurrence and post-transplant diabetes

被引:30
|
作者
Humar, Abhinav [1 ]
Crotteau, Shaina [1 ]
Gruessner, Angelika [1 ]
Kandaswamy, Raja [1 ]
Gruessner, Rainer [1 ]
Payne, William [1 ]
Lake, John [1 ]
机构
[1] Univ Minnesota, Dept Surg, Minneapolis, MN 55455 USA
关键词
immunosuppression; liver transplant; post-transplant diabetes; steroid avoidance;
D O I
10.1111/j.1399-0012.2007.00683.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Steroid minimization regimens have become increasingly popular for kidney transplant recipients. We studied outcomes for liver transplant recipients with a regimen using rapid discontinuation of prednisone (RDP). Results: The study group consisted of 83 recipients transplanted between June 2004 and January 2006. Immunosuppression consisted of tacrolimus, MMF, and two doses of basiliximab with six d of steroids. Patients with underlying autoinunune disorders (PSC, autoimmune hepatitis) were not included as they were maintained on steroids. The control group consisted of 83 recipients transplanted between January 2002 and May 2004. Immunosuppression consisted of tacrolimus, MMF and steroids, with no antibody induction. Mean MELD score at time of transplant was significantly higher in the steroid free group vs. the control group (28 vs. 23, p = 0.02); mean donor age was also higher (42 vs. 37 yr, p = 0.02). Other characteristics including recipient age, cold ischemic time, donor source, and cause of liver disease were similar (p = ns). Mean length of follow-up was 16.1 months in the RDP group and 32 months in the control group; a minimum of six months follow up was present for all patients. Patient and graft survival rates were not statistically different in the two groups (p = ns). Biopsy proven rejection was low in both groups and not significantly different (at one yr post-transplant 11% in the RDP group vs. 12% in control, p = 0.53). Based on protocol biopsy data, histologic recurrence of hepatitis C was demonstrated in 56% of the control group hepatitis C positive recipients vs. 39% in the RDP group (p = 0.05). There was a significantly lower incidence of post-transplant diabetes (PTDM) in the RDP vs. control group (at 6 months post-transplant 12% vs. 32%. p = 0.004). Conclusions: Rapid discontinuation of prednisone in liver transplant recipients is not associated with an increased risk of rejection, and may be associated with lower morbidity, especially PTDM and hepatitis C recurrence.
引用
收藏
页码:526 / 531
页数:6
相关论文
共 50 条
  • [41] The Impact of De Novo Post-Transplant Diabetes on Hepatic Steatosis and Liver Transplant Outcomes
    Reuter, C.
    Lee, R. -A.
    Watkins, R.
    Lieber, S.
    Szempruch, K.
    Gerber, D.
    DeCherney, G.
    Barritt, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2017, 17 : 774 - 774
  • [42] Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil
    Fasola, CG
    Netto, GJ
    Jennings, LW
    Christensen, LL
    Molmenti, EP
    Sanchez, EQ
    Levy, MF
    Goldstein, RM
    Klintmalm, GB
    TRANSPLANTATION PROCEEDINGS, 2002, 34 (05) : 1563 - 1564
  • [43] Hepatitis C virus recurrence in living donor liver transplant recipients
    Rodriguez-Luna, H
    Vargas, HE
    Sharma, P
    Ortiz, J
    De Petris, G
    Balan, V
    Byrne, T
    Moss, A
    Mulligan, D
    Rakela, J
    Douglas, DD
    DIGESTIVE DISEASES AND SCIENCES, 2004, 49 (01) : 38 - 41
  • [44] Impact of Liver Fibrosis in Patients with Post-Liver Transplant Hepatitis C Recurrence.
    Gallegos-Orozco, Juan F.
    Yosephy, Amir
    Noble, Brie
    De Patris, Giovanni
    Aqel, Bashar A.
    Byrne, Thomas J.
    Carey, Elizabeth J.
    Douglas, David D.
    Reddy, Kunam S.
    Rakela, Jorge
    Vargas, Hugo E.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2009, 9 : 377 - 377
  • [45] The predictors of post-transplant coronary events among liver transplant recipients
    Mohammad U. Malik
    Stuart D. Russell
    Aliaksei Pustavoitau
    Matthews Chacko
    Arif M. Cosar
    Carol B. Thompson
    Panagiotis Trilianos
    Nabil N. Dagher
    Andrew M. Cameron
    Ahmet Gurakar
    Hepatology International, 2016, 10 : 974 - 982
  • [46] Current Challenges in the Post-Transplant Care of Liver Transplant Recipients in Germany
    Herzer, Kerstin
    Sterneck, Martina
    Welker, Martin-Walter
    Nadalin, Silvio
    Kirchner, Gabriele
    Braun, Felix
    Malessa, Christina
    Herber, Adam
    Pratschke, Johann
    Weiss, Karl Heinz
    Jaeckel, Elmar
    Tacke, Frank
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (11) : 1 - 23
  • [47] Steroid Withdrawal Using Everolimus in ABO-Incompatible Kidney Transplant Recipients With Post-Transplant Diabetes Mellitus
    Nanmoku, K.
    Shinzato, T.
    Kubo, T.
    Shimizu, T.
    Kimura, T.
    Yagisawa, T.
    TRANSPLANTATION PROCEEDINGS, 2018, 50 (04) : 1050 - 1055
  • [48] POST-TRANSPLANT OBESITY PARADOX IN LIVE DONOR LIVER TRANSPLANT RECIPIENTS
    Ganesh, Swaytha
    Chiu, Wai Kan
    Jorgensen, Dana
    Molinari, Michele
    Tevar, Amit D.
    Hughes, Christopher
    Humar, Abhinav
    Behari, Jaideep
    GASTROENTEROLOGY, 2020, 158 (06) : S1264 - S1264
  • [49] Pre- and post-transplant bacterial infections in liver transplant recipients
    Heldman, Madeleine R.
    Ngo, Stephen
    Dorschner, Peter B.
    Helfrich, Mia
    Ison, Michael G.
    TRANSPLANT INFECTIOUS DISEASE, 2019, 21 (05)
  • [50] Post-Transplant Complications in Recipients of Deceased and Living Donor Liver Transplant
    Samstein, B.
    Smith, A.
    Freise, C.
    Zimmerman, M.
    Baker, T.
    Olthoff, K.
    Fisher, R.
    Merion, R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 2 - 2